ANPI SEC FILINGS http://livermore.brand.edgar-online.com/?sym=anpi
FUNDS WHO OWN ANPI
| Company Name |
Shares
Held  |
Change
in Shares |
% Change
Shares |
$ Market
Value |
% of
Portfolio |
% of
TSO |
Report
Date |
| LETKO, BROSSEAU & ASSOCIATES INC |
7,898,180 |
(206,450) |
-2.55 |
$59,473,295 |
0.57 |
9.29 |
06/30/07 |
| FRANKLIN RESOURCES INC |
6,221,985 |
115,715 |
1.90 |
$46,851,547 |
0.03 |
7.32 |
06/30/07 |
| NATCAN INVESTMENT MANAGEMENT INC |
6,017,624 |
(4,054,199) |
-40.25 |
$45,312,709 |
0.49 |
7.08 |
09/30/07 |
| WEST COAST ASSET MANAGEMENT INC |
3,889,195 |
809,425 |
26.28 |
$29,285,638 |
10.47 |
4.57 |
06/30/07 |
| STATE OF WISCONSIN INVESTMENT BOARD |
3,414,878 |
468,950 |
15.92 |
$25,714,031 |
0.26 |
4.02 |
06/30/07 |
| LEGG MASON INC |
3,400,305 |
(647,950) |
-16.01 |
$25,604,297 |
0.01 |
4.00 |
06/30/07 |
| FREESTONE CAPITAL MANAGEMENT INC |
2,133,096 |
2,133,096 |
100.00 |
$16,062,213 |
4.44 |
2.51 |
09/30/07 |
| RBC ASSET MANAGEMENT INC |
1,874,300 |
(178,800) |
-8.71 |
$14,113,479 |
0.05 |
2.20 |
06/30/07 |
| BECKER CAPITAL MANAGEMENT INC |
1,599,161 |
343,504 |
27.36 |
$12,041,682 |
0.64 |
1.88 |
06/30/07 |
| LAZARD ASSET MANAGEMENT LLC |
1,422,880 |
920,580 |
183.27 |
$10,714,286 |
0.02 |
1.67 |
09/30/07 |
| BLACKROCK INVESTMENT MANAGEMENT, LLC |
1,422,800 |
(1,517,097) |
-51.60 |
$10,713,684 |
0.01 |
1.67 |
06/30/07 |
| LEHMAN BROTHERS HOLDINGS INC |
1,281,440 |
1,269,238 |
10,401.88 |
$9,649,243 |
0.03 |
1.51 |
06/30/07 |
| MACKENZIE FINANCIAL CORP |
1,145,391 |
268,999 |
30.69 |
$8,624,794 |
0.03 |
1.35 |
06/30/07 |
| BARCLAYS GLOBAL INVESTORS NA /CA/ |
734,239 |
(423,005) |
-36.55 |
$5,528,820 |
0.00 |
0.86 |
06/30/07 |
| LIBERTY RIDGE CAPITAL, INC. |
725,299 |
225,970 |
45.25 |
$5,461,501 |
1.02 |
0.85 |
06/30/07 |
| WELLS FARGO & CO/MN |
723,900 |
(63,500) |
-8.06 |
$5,450,967 |
0.01 |
0.85 |
06/30/07 |
| GOODMAN & COMPANY, INVESTMENT COUNSEL LTD. |
717,200 |
500 |
0.07 |
$5,400,516 |
0.07 |
0.84 |
06/30/07 |
| TD ASSET MANAGEMENT INC |
602,759 |
178,845 |
42.19 |
$4,538,775 |
0.02 |
0.71 |
06/30/07 |
| DEUTSCHE BANK AG\ |
540,781 |
491,698 |
1,001.77 |
$4,072,081 |
0.00 |
0.64 |
06/30/07 |
| MORGAN STANLEY |
514,427 |
(824,535) |
-61.58 |
$3,873,635 |
0.00 |
0.61 |
06/30/07 |
| DELAWARE MANAGEMENT BUSINESS TRUST |
497,400 |
497,400 |
100.00 |
$3,745,422 |
0.01 |
0.59 |
06/30/07 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
471,777 |
471,777 |
100.00 |
$3,552,481 |
0.04 |
0.55 |
06/30/07 |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC |
462,577 |
(200,000) |
-30.19 |
$3,483,205 |
0.02 |
0.54 |
06/30/07 |
| VOYAGEUR ASSET MANAGEMENT INC |
402,752 |
232,552 |
136.63 |
$3,032,723 |
0.04 |
0.47 |
06/30/07 |
| KENNEDY CAPITAL MANAGEMENT INC |
350,877 |
(97,400) |
-21.73 |
$2,642,104 |
0.06 |
0.41 |
06/30/07 |
Angiotech Cuts 2007 Revenue Outlook
Friday October 19, 12:09 pm ET
Angiotech Pharma Cuts 2007 Outlook, Citing Lower Royalty Revenue, Delayed Regulatory OK
NEW YORK (AP) -- Angiotech Pharmaceuticals Inc. on Friday cut its 2007 outlook, citing weak drug-eluting stent sales from partner Boston Scientific Corp.
Shares of the specialty pharmaceutical and medical device company plummeted $2.49, or 33.1 percent, to $5.04 in midday trading. The stock earlier traded as low as $4.86, after ranging from $5.28 to $9.81 for the past year.
ADVERTISEMENT
 |
if(window.yzq_d==null)window.yzq_d=new Object();
window.yzq_d['AW0IONibyhU-']='&U=13bp9bgc9%2fN%3dAW0IONibyhU-%2fC%3d617051.11403373.12073149.1383221%2fD%3dLREC%2fB%3d4953865';
|
The company predicted adjusted earnings before interest, taxes, depreciation and amortization of $47 million to $50 million for the year. Previously, Angiotech forecast EBITDA of $85 million to $95 million for 2007.
Angiotech also lowered its medical product revenue outlook to a range of $171 million to $173 million, from a previous estimate of $190 million to $210 million.
Angiotech cut its 2007 royalty revenue outlook to a range of $118 million to $120 million, from a prior forecast of $130 million to $135 million. Angiotech records royalty revenue from Boston Scientific's drug-eluting cardiac stents which use Angiotech's paclitaxel drug coating.
Boston Scientific reported third-quarter sales of paclitaxel-eluting stents fell to $448 million from $572 million a year ago.
Analysts polled by Thomson Financial expect Angiotech to report 2007 revenue of $315.3 million.
Angiotech said it expected modestly lower full-year revenue from the recently acquired American Medical Instruments Inc. compared to initial forecasts, due in part to its discontinuation of certain product lines.
Angiotech also cited unexpectedly long regulatory review times, primarily for its Vascular Wrap product candidate in the European Union. Angiotech said it had expected the product candidate to be approved for sale in the EU by the third quarter. Now it believes that won't occur until the first half of 2008.
Angiotech also cut its 2007 sales guidance for new product lines to $10 million to $30 million.